Researchers at Queen’s have developed a highly innovative new enzyme biomarker test that has the potential to indicate diseases and bacterial contamination saving time, money and possibly lives.
The test, developed by scientists at the Institute for Global Food Security (IGFS) at Queen’s, can detect enzyme markers of disease known as proteases in humans, animals and food products.
Proteases are crucial for microorganism growth and are responsible for the progression of many diseases.
Levels of these enzyme markers can be highly elevated in the urine of patients with diabetic kidney disease, or at the sites of infected wounds. Similarly, in cows, an elevation of proteases in their milk can reveal diseases such as bovine mastitis, a type of mammary gland infection. In food, proteases produced by bacteria contaminated in meat and dairy products can lead to rancidity, as well as decreased shelf life and quality.
Current protease detection methods are costly, time-consuming and are not always effective. Scientists at the IGFS have developed a nanosensor which has resulted in sensitive, fast and cost-effective protease detection in milk and urine.
Dr Claire McVey, Queen’s researcher and co-author on the study published in leading journal Nano Research, explained: “Not only is the test cheap to produce, but it can be used anywhere and is not reliant on laboratory conditions.
“Eliminating the need to carry out tests in a laboratory setting is life-changing. As well as being cost-effective, it means faster diagnosis.”
The gold-nanoparticle based nanosensor devised by Queen’s researchers indicates when proteases are present through a visible colour-change reaction. Gold nanoparticles are well known for their capability in speeding up the oxidization of a chemical called tetramethylbenzidine (TMB), visible through a vivid blue-colour formation.
When casein (a molecule present in milk) is added to gold nanoparticles, it surrounds the nanoparticles acting as a protective surface barrier. When TMB is introduced, the casein prevents the oxidization reaction meaning there is no or only a slight colour change.
Where proteases are present, they ‘eat’ the protective casein barrier, exposing the surface of the gold nanoparticles. In this instance, when TMB is added, the proteases have removed the casein meaning oxidization occurs quickly causing a fast change in colour.
Queen’s researcher Dr Cuong Cao, a Lecturer in Advanced Micro- and Nano-Diagnostics, and the lead academic on the study: “When we add TMB to the casein-covered gold nanoparticles, we can tell virtually instantly if proteases are present by whether or not the solution turns blue. Normally such testing takes much longer.”
Using this approach, proteases can be detected within 90 minutes without the need for complicated or expensive laboratory equipment.
In addition, the ‘ingredients’ for making the nanosensor are readily available and low cost. Gold nanoparticles can be produced in abundance, with little restriction on storage requirements, making it a durable and cheap substance.
The approach developed by the Queen’s researchers was tested on milk and urine but it could be adapted for a number of other applications. Dr Cao explained: “Using molecules other than casein to coat the surface has the potential to detect other types of enzyme biomarkers. For example, coating the nanoparticles with lipids could detect the lipase enzyme, which could help in the diagnosis of diseases such as pancreatitis.
“Following full validation of this test, we would like to explore how we could expand the application to detect a host of other diseases or contaminated foods.
“This new approach will enable the identification of enzyme biomarkers at the point of care. It could change the landscape of how enzyme biomarkers are detected and diagnosed, making an impact not only on food safety, but on the diagnosis of enzyme-related illnesses among animals and humans.
“The potential scope for this test is huge.”
Professor Chris Elliott, founder of the Institute for Global Food Security and a co-investigator in the study commented: “The ability to diagnose disease or contamination quickly can have a huge impact on how serious problems can be dealt with.
“The ultra-low cost of the system will help reduce costs of testing and could transform the amount of testing performed in the developing world.”
The Latest on: Enzyme biomarker
via Google News
The Latest on: Enzyme biomarker
- Can metabolic biomarkers help clinicians stratify adverse outcome risk in COVID-19 patients?on January 20, 2021 at 5:43 am
A recent study describes the alterations in lipids and other parameters that define the state of dysfunctional metabolism in acute COVID-19 illness.
- World-first biomarker test can predict depression and bipolar disorderon January 19, 2021 at 7:57 pm
Australian scientists have developed and validated a world-first test that is claimed to accurately measure levels of a brain protein known to be associated with depression and bipolar disorder. The ...
- Potential new biomarker for depression and bipolar disorderon January 19, 2021 at 4:42 am
UniSA scientists have developed the world's first test to accurately predict mood disorders in people, based on the levels of a specific protein found in the brain.
- Researchers find potential biomarkers of Parkinson's diseaseon January 18, 2021 at 8:58 pm
A research team led by Nagoya University in Japan has found that blood pressure, the hematocrit (the percentage of red blood cells in blood), and serum cholesterol levels change in patients with ...
- Global Alzheimer's Disease Diagnostics and...on January 18, 2021 at 2:00 pm
The "Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been ...
- FDA Approves Crizotinib in Pediatric ALK+ Relapsed or Refractory Systemic ALCLon January 14, 2021 at 1:47 pm
The FDA granted approval to the antineoplastic tyrosine kinase inhibitor, crizotinib, as treatment of pediatric patients 1 year of age and older and young adults with ALK alteration-positive relapsed ...
- HTR2A Gene Changes Found Only in Progressive MS May Be New Biomarkeron January 13, 2021 at 7:53 am
Scientists have discovered epigenetic changes in a gene called HTR2A, found only in immune cells isolated from people with secondary progressive multiple sclerosis (SPMS), a study reported. These ...
- Immune response biomarkers, novel pathways in four marine mollusk specieson January 12, 2021 at 2:17 pm
A new study assessed immune responses in four economically important marine mollusk species -- the blue mussel, soft-shell clam, Eastern oyster, and Atlantic jackknife clam -- and identified new ...
- Scientists study use of abundant enzyme in tumor cells to monitor cancer treatmenton January 12, 2021 at 1:06 pm
The abundant presence of an enzyme known as low molecular weight protein tyrosine phosphatase (LMWPTP) in tumor cells has long been considered an indicator of cancer aggressiveness and metastatic ...
- Study identifies immune response biomarkers, novel pathways in four marine mollusc specieson January 12, 2021 at 8:16 am
A new study involving the University of Maine assessed immune responses in four economically important marine mollusc species -- the blue mussel, soft-shell clam, Eastern oyster, and Atlantic ...
via Bing News